维泊妥珠单抗治疗弥漫性大B细胞淋巴瘤的药物经济学研究系统评价  

Pharmacoeconomic study of polatuzumab vedotin in treating diffuse large B-cell lymphoma:a systematic review

作　　者：李理总 罗兴献 周越 黄琳[1] 贾月萍[2] 封宇飞 张晓红[1] LI Lizong;LUO Xingxian;ZHOU Yue;HUANG Lin;JIA Yueping;FENG Yufei;ZHANG Xiaohong(Department of Pharmacy,Peking University People’s Hos-pital,Beijing 100044,China;Department of Pediatrics,Peking University People’s Hos-pital,Beijing 100044,China;Clinical Trial Site,Peking University People’s Hos-pital,Beijing 100044,China)

机构地区：[1]北京大学人民医院,药学部,北京100044 [2]北京大学人民医院,儿科,北京100044 [3]北京大学人民医院,临床试验机构,北京100044

出　　处：《中国医院药学杂志》2025年第5期510-515,528,共7页Chinese Journal of Hospital Pharmacy

基　　金：国家自然科学基金青年项目(编号:72304168)。

摘　　要：目的:系统评价维泊妥珠单抗的药物经济学价值以及经济性,为我国医保准入和医院药品遴选等相关医疗卫生决策提供参考。方法:计算机检索中国知网、万方数据知识服务平台、维普、PubMed、EMBASE和Cochrane library等数据库,查询建库至2024年4月1日公开发表的维泊妥珠单抗药物经济学研究,对研究设计、研究质量、药物经济学评价结果及敏感性分析等方面进行系统分析。结果:共纳入8篇来自4个国家和地区的研究,主要药物经济学评价方法为成本-效用分析,3项研究采用分区生存模型,5项研究采用马尔可夫模型。文献研究结果显示,在治疗复发或难治性弥漫性大B细胞淋巴瘤方面,含维泊妥珠单抗的治疗方案,与传统一线治疗方案相比具有成本-效果优势,与塔法司他单抗+来那度胺治疗方案相比不具有成本-效果优势。在弥漫性大B细胞淋巴瘤初治方面,除1项研究外,含维泊妥珠单抗的治疗方案,与一线治疗方案相比均有成本-效果优势。结论:目前有关维泊妥珠单抗治疗弥漫性大B细胞淋巴瘤的经济学评价研究相对较少,研究背景、对照组、模型假设的差异可能导致研究结论不同。在中国人群中,维泊妥珠单抗治疗弥漫性大B细胞淋巴瘤的经济性有待进一步研究验证。OBJECTIVE To systematically review economic evaluations of polatuzumab vedotin,and to provide an evidence to help decision makers improve the utilization of medical resources.METHODS Studies published from the establishment of the libraries to April 1,2024 were searched in China National Knowledge Infrastructure(CNKI),WanFang Data,VIP databases,PubMed,EMBASE and Cochrane library.Research model,pharmacoeconomic evaluation results and sensitivity analysis were systematically reviewed.A systematic analysis was conducted on the study design,study quality,pharmacoeconomic evaluation results and sensitivity analysis.RESULTS A total of eight studies from four countries and regions were included.The main phar⁃macoeconomic evaluation method was cost-effectiveness analysis.Three studies used the partition survival model and five studies used the Markov model.Literature review showed that tretatment regimen containing polatuzumab vedotin had a cost-effectiveness advantage in treating relapsed or refractory diffuse large B-cell lymphoma(DLBCL)compared with the traditional first-line treatment,but inferior to tafasitamab and lenalidomide treatment.Except for one study,the initial treatment regimen con⁃taining polatuzumab vedotin had cost-effectiveness advantages compared with the first-line treatment of DLBCL.CONCLUSION There are limited studies evaluating the cost-economics of polatuzumab vedotin in the treatment of DLBCL,and the heterogeneity of study settings,control groups,and modeling assumptions may contribute to the inconsistent results.Fur⁃ther studies are needed to verify the economics of polatuzumab vedotin for DLBCL in the Chinese population.

关 键 词：维泊妥珠单抗 弥漫性大B细胞淋巴瘤 药物经济学 系统评价 

分 类 号：R956[医药卫生—药学]